UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 15, 2021
SQZ BIOTECHNOLOGIES COMPANY
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-39662 |
|
46-2431115 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
200 Arsenal Yards Blvd, Suite 210
Watertown, MA 02472
(Address of principal executive offices) (Zip Code)
(617) 758-8672
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbols |
|
Name of each exchange on which registered |
|
Common Stock, |
|
SQZ |
|
The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
SQZ Biotechnologies Company (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 15, 2021, at which a quorum was present. As of April 22, 2021, the record date for the Annual Meeting, there were 27,881,722 outstanding shares of the Company’s common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 26, 2021. The voting results for each proposal are also described below.
Item 1: To elect Marc Elia and Pushkal Garg, M.D. as Class I directors to serve until the 2024 annual meeting of stockholders and until their respective successors shall have been duly elected and qualified.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class I Director Nominee |
|
For |
|
|
Withheld |
|
|
Broker Non- |
|
|||
|
Marc Elia |
|
|
13,961,311.96 |
|
|
670,997.00 |
|
|
|
1,608,096.00 |
|
|
|
Pushkal Garg, M.D. |
|
|
13,964,242.96 |
|
|
668,066.00 |
|
|
|
1,608,096.00 |
|
|
Item 2: To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
16,236,035.96 |
|
2,003.00 |
|
2,366.00 |
|
0.00 |
Based on the foregoing votes, Marc Elia and Pushkal Garg, M.D. were elected as Class I directors, and Item 2 was approved.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
SQZ BIOTECHNOLOGIES COMPANY |
||
|
|
|
|
|
|
Date: June 17, 2021 |
By: |
|
/s/ Lawrence Knopf |
|
|
|
|
Lawrence Knopf |
|
|
|
|
General Counsel |